Company Description
Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain.
Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.
The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial.
It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2.
The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.
| Country | United States |
| Founded | 2020 |
| IPO Date | Jan 7, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 69 |
| CEO | Dr. Ivana Magovcevic-Liebisch J.D., Ph.D. |
Contact Details
Address: 100 Forge Road, Suite 700 Watertown, Massachusetts 02472 United States | |
| Phone | 857-254-4445 |
| Website | vigilneuro.com |
Stock Details
| Ticker Symbol | VIGL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $14.00 |
| CIK Code | 0001827087 |
| CUSIP Number | 92673K108 |
| ISIN Number | US92673K1088 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ivana Magovcevic-Liebisch J.D., Ph.D. | President, Chief Executive Officer and Director |
| Jennifer Ziolkowski CPA | Chief Financial Officer |
| Sharon Morani | Senior Director of Facilities and Operations |
| Dr. David Gray Ph.D. | Chief Scientific Officer |
| Leah Gibson | Vice President of Investor Relations and Corporate Communications |
| Christopher Verni J.D. | General Counsel and Corporate Secretary |
| April Effort M.B.A., M.S. | Vice President and Head of Corporate Development |
| Evan A. Thackaberry DABT, Ph.D. | Senior Vice President and Head of Early Development |
| Christian Mirescu Ph.D. | Vice President and Head of Neuroimmunology |
| Weeteck Yeo Ph.D. | Senior Vice President of Strategic Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 22, 2024 | ARS | Filing |
| Apr 22, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 22, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 12, 2024 | PRE 14A | Other preliminary proxy statements |
| Mar 29, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Mar 26, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 26, 2024 | 10-K | Annual Report |
| Mar 26, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |